Floatz logo

Rivoceranib

Bone Mineral Density

Anhui Provincial HospitalSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Bone Mineral Density cohort.

Asset / SponsorPhaseRating
Famitinib
Anhui Provincial Hospital
Phase 3B
Fluzoparib
Anhui Provincial Hospital
Phase 3B
VITAMIN D
Zagazig University
Phase 2CCC

Same molecule, other indications

Rivoceranib is also rated in:

gastric cancerDormant
BBB
Indicative ·
73 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
72 / 100
View asset →
ApatinibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →